Cargando…

Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma

This randomized phase II study evaluated two schedules of the marine compound Plitidepsin with or without co-administration of L-carnitine in patients with renal cell carcinoma. Patients had adequate performance status and organ function. The primary endpoint was the rate of disease control (no prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schöffski, Patrick, Guillem, Vincente, Garcia, Margarita, Rivera, Fernando, Tabernero, Josep, Cullell, Martin, Lopez-Martin, Jose Antonio, Pollard, Patricia, Dumez, Herlinde, del Muro, Xavier Garcia, Paz-Ares, Luis
Formato:	Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666889/ https://www.ncbi.nlm.nih.gov/pubmed/19370171 http://dx.doi.org/10.3390/md7010057

Ejemplares similares

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
por: Dumez, Herlinde, et al.
Publicado: (2009)

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts
por: Delgado-Calle, Jesus, et al.
Publicado: (2019)

Plitidepsin for multiple myeloma
Publicado: (2019)

Effect of Aplidin in acute lymphoblastic leukaemia cells
por: Erba, E, et al.
Publicado: (2003)

Plitidepsin: design, development, and potential place in therapy
por: Alonso-Álvarez, Sara, et al.
Publicado: (2017)

Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin™
por: Losada, A, et al.
Publicado: (2004)

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013)

Antiangiogenic activity of aplidine, a new agent of marine origin
por: Taraboletti, G, et al.
Publicado: (2004)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine
por: Erba, E, et al.
Publicado: (2002)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
por: Martinez, Miguel Angel
Publicado: (2021)

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
por: Spicka, Ivan, et al.
Publicado: (2019)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
por: Varona, Jose F, et al.
Publicado: (2022)

Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy
por: Guisado-Vasco, P., et al.
Publicado: (2021)

Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis
por: Soto-Matos, Arturo, et al.
Publicado: (2011)

c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity
por: Muñoz-Alonso, María J., et al.
Publicado: (2013)

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Mateos, María Victoria, et al.
Publicado: (2022)

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis
por: Sachse, Martin, et al.
Publicado: (2022)

Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19
por: Papapanou, Michail, et al.
Publicado: (2021)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis
por: Varona, Jose F., et al.
Publicado: (2023)

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin
por: Losada, Alejandro, et al.
Publicado: (2016)

Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and the Implications of New Biomarkers
por: Schöffski, Patrick
Publicado: (2022)

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
por: Awada, Ahmad, et al.
Publicado: (2015)

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells.
por: Depenbrock, H., et al.
Publicado: (1998)

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
por: White, Kris M., et al.
Publicado: (2021)

Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations
por: Vishvakarma, Vijay Kumar, et al.
Publicado: (2021)

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
por: Rodon, Jordi, et al.
Publicado: (2021)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
por: Giesen, Alexander, et al.
Publicado: (2023)

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
por: Mateo, Joaquin, et al.
Publicado: (2016)

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma
por: Kim, Young-Il, et al.
Publicado: (2013)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia
por: Guisado-Vasco, P., et al.
Publicado: (2022)

Carnitine and Depression
por: Liu, Ting, et al.
Publicado: (2022)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hvrltkd57pn6t7ip7g6gc4tida